Several monoclonal antibodies have already been applied in the imaging and treating of EGFR-positive cancers, including cetuximab, panitumumab, nimotuzumab, etc., targeting the extracellular domain of EGFR [43,44,45]. The gene discussed is EGFR; the disease is cancer.